Trials / Completed
CompletedNCT00394472
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an Incomplete Response to PPI.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 244 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 17 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD3355 |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2006-11-01
- Last updated
- 2013-03-18
- Results posted
- 2013-03-18
Locations
38 sites across 8 countries: Australia, Belgium, France, Germany, Hungary, Netherlands, Norway, Romania
Source: ClinicalTrials.gov record NCT00394472. Inclusion in this directory is not an endorsement.